​Ocular Therapeutix faces fraud allegations as FDA rejects eye drug

Bedford eye care biotech Ocular Therapeutix saw its share price plummet on Wednesday after the FDA rejected its lead drug for the second time. To make matters worse, the company and its top executives are now facing fraud allegations in federal court. Ocular (Nasdaq: OCUL) said after markets closed on Tuesday that the FDA had denied its application for Dextenza, a tiny insert that is placed in the eye and delivers a corticosteroid to treat pain following surgical procedures. Regulators cited manufacturing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news